Huntington National Bank’s CASI Pharmaceuticals CASI Stock Holding History

Huntington National Bank’s Portfolio CASI Stock Details CASI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2	Closed	–	–	1662
2018 Q3	$0	Buy	+2	New	+$140	﹤0.01%	1684

Other funds holding CASI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WSCM

Wellington Shields Capital Management New York $666M AUM 45.43% 1-Year Est. Return

WSC

Wellington Shields & Co New York $392M AUM 30.65% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Huntington National Bank's CASI Position: Q4 2018 in Review

Huntington National Bank sold out of CASI Pharmaceuticals (CASI) in Q4 2018, closing a stake of 2 shares.

Huntington National Bank first reported a position in CASI in Q3 2018 and held it in 1 quarter. The position peaked at $0 in Q3 2018. 54 funds tracked by Wall St. Rank hold CASI as of Q4 2018.

Huntington National Bank reported no remaining CASI Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Huntington National Bank sold 2 CASI Pharmaceuticals shares in Q4 2018.
Huntington National Bank first reported a position in CASI Pharmaceuticals in Q3 2018 and held it in 1 quarter.
Huntington National Bank's CASI Pharmaceuticals position peaked at $0 in Q3 2018.
54 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q4 2018.

Based on Huntington National Bank's 13F filing for Q4 2018, filed 28 Jan 2019.